Download PDF
Am J Perinatol 2009; 26(3): 235-245
DOI: 10.1055/s-0028-1103515
© Thieme Medical Publishers

A Randomized, Double-Blind, Placebo-Controlled Trial on Intravenous Ibuprofen L-Lysine for the Early Closure of Nonsymptomatic Patent Ductus Arteriosus within 72 Hours of Birth in Extremely Low-Birth-Weight Infants

Jacob V. Aranda1 , Ronald Clyman2 , Blair Cox3 [†] , Bart Van Overmeire4 , Paul Wozniak5 , Ilene Sosenko6 , Waldemar A. Carlo7 , Robert M. Ward8 , Robert Shalwitz9 , Geraldine Baggs9 , Anand Seth9 , Laszlo Darko10 [†]
  • 1Pediatric Pharmacology Research Unit Network, The Children's Hospital of Michigan, Wayne State University, Detroit, MI
  • 2University of California, San Francisco, San Francisco, California
  • 3Department of Pediatrics, Neonatal-Perinatal Medicine Division, University of Texas, Southwestern Medical Center, Dallas, Texas
  • 4University of Antwerp, Antwerp University Hospital, Edegem, Belgium
  • 5University of California, San Diego, San Diego, California
  • 6Jackson Memorial Hospital, Miami, Florida
  • 7Division of Neonatology, University of Alabama at Birmingham, Birmingham, Alabama
  • 8Pediatric Neonatology, University of Utah Hospital, Salt Lake City, Utah
  • 9Abbott Laboratories, Columbus, Ohio
  • 10Farmacon IL, Inc., Stratford, Connecticut
Further Information

Publication History

Publication Date:
09 December 2008 (online)

   Permissions and Reprints

ABSTRACT

A multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of intravenous (IV) ibuprofen (L-lysine) for the early closure of nonsymptomatic patent ductus arteriosus (PDA) within 72 hours of birth in extremely low-birth-weight (ELBW) infants with evidence of ductal shunting by echocardiogram. Eleven sites enrolled 136 infants with nonsymptomatic early PDA (gestational age < 30 weeks; body weight 500 to 1000 g) to receive a 3-day course (10 mg/kg, 5 mg/kg, and 5 mg/kg) of IV ibuprofen (n = 68) or placebo (n = 68). Cardiac echocardiogram was performed on study days 1 and 14, and with rescue. Infants were followed to 36 weeks postconceptional age. Patient demographics, mean (standard deviation), were similar between ibuprofen and placebo: birth weight: 798.5 g (128.7) versus 797.3 g (132.8); gestational age: 26.1 weeks (1.3) versus 26.2 weeks (1.4); and age at first dose: 1.5 days (0.7). The intent-to-treat analysis of the primary endpoint, subjects rescued, died, or dropped through study day 14, was 21/68 (30.9%) with ibuprofen and 36/68 (52.9%) for placebo (p = 0.005). Death, intraventricular hemorrhage, necrotizing enterocolitis, daily fluid intake/output, liver function, bronchopulmonary dysplasia, and retinopathy of prematurity did not differ. A trend toward decreased periventricular leukomalacia by ibuprofen was noted. IV ibuprofen was effective and safe in the early closure of PDA in preterm neonates.

KEYWORDS

Ibuprofen - patent ductus arteriosus - premature newborn - cyclooxygenase inhibitors - randomized clinical trial

REFERENCES

  • 1 Hammerman C. Patent ductus arteriosus.  Clin Perinatol. 1995;  22 457-477
    CrossrefPubMedGoogle Scholar
  • 2 Krueger E, Mellander M, Bratton D, Cotton R. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin.  J Pediatr. 1987;  111 749-754
    PubMedGoogle Scholar
  • 3 Dudell G G, Gersony W M. Patent ductus arteriosus in neonates with severe respiratory distress syndrome.  J Pediatr. 1984;  104 915-920
    CrossrefPubMedGoogle Scholar
  • 4 Rubaltelli F F, Dani C, Reali M F et al.. Acute neonatal respiratory distress in Italy: a one-year prospective study.  Acta Paediatr. 1998;  87 1261-1268
    Google Scholar
  • 5 Hammerman C, Kaplan M. Comparative tolerability of pharmacological treatment for patent ductus arteriosus.  Drug Saf. 2001;  24 537-551
    CrossrefPubMedGoogle Scholar
  • 6 Clyman R I. Ibuprofen and patent ductus arteriosus.  N Engl J Med. 2000;  343 728-730
    CrossrefPubMedGoogle Scholar
  • 7 Cotton R B, Stahlman M T, Bender H W et al.. Randomized trial of early closure of symptomatic patent ductus arteriosus in small preterm infants.  J Pediatr. 1978;  93 647-651
    CrossrefPubMedGoogle Scholar
  • 8 Gersony W M, Peckham G J, Ellison R C, Miettinen O S, Nadas A S. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.  J Pediatr. 1983;  102 895-906
    CrossrefPubMedGoogle Scholar
  • 9 Cooke L, Steer P, Woodgate P. Indomethacin for asymptomatic patent ductus arteriosus in preterm infants.  Cochrane Database Syst Rev. 2003;  (2):CD003745 , DOI: 10.1002/14651858.CD003745
    PubMedGoogle Scholar
  • 10 Fowlie P W, Davis P G. Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants.  Cochrane Database Syst Rev. 2006;  (3) , CD000174. DOI: 10.1002/14651858.CD000174
    PubMedGoogle Scholar
  • 11 Yeh T F, Luken J A, Thalji A, Raval D, Carr I, Pildes R S. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus—a double-blind controlled study.  J Pediatr. 1981;  98 137-145
    PubMedGoogle Scholar
  • 12 Rennie J M, Doyle J, Cooke R W. Early administration of indomethacin to preterm infants.  Arch Dis Child. 1986;  61 233-238
    PubMedGoogle Scholar
  • 13 Narayanan M, Cooper B, Weiss H, Clyman R I. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure.  J Pediatr. 2000;  136 330-337
    CrossrefPubMedGoogle Scholar
  • 14 Keller R L, Clyman R I. Persistent Doppler flow predicts lack of response to multiple courses of indomethacin in premature infants with recurrent patent ductus arteriosus.  Pediatrics. 2003;  112(3 Pt 1) 583-587
    CrossrefPubMedGoogle Scholar
  • 15 Coceani F, White E, Bodach E, Olley P M. Age-dependent changes in the response of the lamb ductus arteriosus to oxygen and ibuprofen.  Can J Physiol Pharmacol. 1979;  57 825-831
    PubMedGoogle Scholar
  • 16 Varvarigou A, Bardin C L, Beharry K, Chemtob S, Papageorgiou A, Aranda J V. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.  JAMA. 1996;  275 539-544
    Google Scholar
  • 17 Van Overmeire B, Follens I, Hartmann S, Creten W L, Van Acker K J. Treatment of patent ductus arteriosus with ibuprofen.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 F179-184
    CrossrefPubMedGoogle Scholar
  • 18 Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effect of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.  J Pediatr. 1997;  131 549-554
    PubMedGoogle Scholar
  • 19 Grosfeld J L, Kamman K, Gross K et al.. Comparative effects of indomethacin, prostaglandin E1 and ibuprofen on bowel ischemia.  J Pediatr Surg. 1983;  18 738-742
    CrossrefPubMedGoogle Scholar
  • 20 Malcom D D, Segar J L, Robillard J E, Chemtob S. Indomethacin compromises hemodynamics during positive-pressure ventilation independently of prostanoids.  J Appl Physiol. 1993;  74 1672-1678
    PubMedGoogle Scholar
  • 21 Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards A D. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.  Pediatr Res. 2000;  47 36-42
    CrossrefPubMedGoogle Scholar
  • 22 Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubatelli F F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.  J Pediatr. 1999;  135 733-738
    CrossrefPubMedGoogle Scholar
  • 23 Shah S S, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.  Cochrane Database Syst Rev. 2006;  , (1):CD004213. DOI: 10.1002/14651858.CD004213.pub2
    PubMedGoogle Scholar
  • 24 Van Overmeire B, Allegaert K, Casaer A et al.. Prophylactic ibuprofen in premature infants: a multicentre, randomized, double-blind, placebo-controlled trial.  Lancet. 2004;  364 1945-1949
    CrossrefPubMedGoogle Scholar
  • 25 Van Overmeire B, Smets K, Lecoutere D et al.. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.  N Engl J Med. 2000;  343 674-681
    CrossrefPubMedGoogle Scholar
  • 26 Fanaroff A A, Stoll B J, Wright L L et al.. Trends in neonatal morbidity and mortality for very low birthweight infants.  Am J Obstet Gynecol. 2007;  196 147.e1-e8
    CrossrefPubMedGoogle Scholar
  • 27 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld C R. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.  Pediatrics. 2006;  117 1113-1121
    CrossrefPubMedGoogle Scholar
  • 28 Gonzalez A, Sosenko I R, Chandar J et al.. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less.  J Pediatr. 1996;  128 470-478
    CrossrefPubMedGoogle Scholar
  • 29 Martin J A, Hamilton B E, Sutton P D et al.. Births: Final data for 2005. National vital statistics reports; Vol. 56, No. 6. Hyattsville, MD; National Center for Health Statistics 2007
    Google Scholar
  • 30 Australian New Zealand Clinical Trials Registry .Targeting of treatment of the patent ductus arteriosus using early echocardiography (DETECT). ID#: ACTRN12608000295347. Available at: http://www.anzctr.org.au/trial_view.aspx?ID=82886 Accessed August 6, 2008
    Google Scholar
  • 31 Efron B. Forcing a sequential experiment to be balanced.  Biometrika. 1971;  58 403-417
    CrossrefPubMedGoogle Scholar
  • 32 Aranda J V, Varvarigou A, Beharry K et al.. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant.  Acta Paediatr. 1997;  86 289-293
    CrossrefPubMedGoogle Scholar
  • 33 Bell M J. Neonatal necrotizing enterocolitis.  N Engl J Med. 1978;  298 281-282
    PubMedGoogle Scholar
  • 34 Gournay V, Roze J C, Kuster A et al.. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 1939-1944
    CrossrefPubMedGoogle Scholar
  • 35 Chemtob S, Beharry K, Rex J, Varma D R, Aranda J V. Prostanoids determine the range of cerebral blood flow autoregulation of newborn piglets.  Stroke. 1990;  21 777-784
    PubMedGoogle Scholar
  • 36 Dani C, Bertini G, Pezzati M et al.. Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study.  Pediatrics. 2005;  115 1529-1535
    CrossrefPubMedGoogle Scholar
  • 37 Ment L R, Oh W, Ehrenkranz R A et al.. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial.  J Pediatr. 1994;  124 951-955
    CrossrefPubMedGoogle Scholar
  • 38 Papile L A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm.  J Pediatr. 1978;  92 529-534
    CrossrefPubMedGoogle Scholar
  • 39 Barkovich AJ Pediatric Neuroimaging. 3rd Ed. Philadelphia; Lippincott Williams and Wilkins 2000: 180-4
    Google Scholar
  • 40 Thomas R L, Parker G C, Van Overmeire B, Aranda J V. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.  Eur J Pediatr. 2005;  164 135-140
    CrossrefPubMedGoogle Scholar
  • 41 Romagnoli C, De Carolis M P, Papacci P et al.. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates.  Clin Pharmacol Ther. 2000;  67 676-683
    CrossrefPubMedGoogle Scholar
  • 42 Gournay V, Savagner C, Thiriez G, Kuster A, Rozé J C. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants.  Lancet. 2002;  359 1486-1488
    CrossrefPubMedGoogle Scholar
  • 43 Hasan J, Beharry K, Gharraee Z et al.. Early postnatal ibuprofen and indomethacin effects in suckling and weanling rat kidneys.  Prostaglandins Other Lipid Mediat. 2008;  85 81-88
    CrossrefPubMedGoogle Scholar
  • 44 Schmidt B, Roberts R, Davis P et al.. The International Caffeine for Apnea of Prematurity (CAP) Trial. Preliminary analysis of outcome at corrected age of 18 to 21 months. Pediatric Academic Societies Meeting May 5, 2007 Abstract 5130.1, Toronto, Canada
    Google Scholar
  • 45 Kinsella J P, Cutter G R, Walsh W F et al.. Early inhaled nitric oxide therapy in premature newborns with respiratory failure.  N Engl J Med. 2006;  355 354-364
    CrossrefPubMedGoogle Scholar
  • 46 Edwards A D, Tan S. Perinatal infections, prematurity and brain injury.  Curr Opin Pediatr. 2006;  18 119-124
    CrossrefPubMedGoogle Scholar
  • 47 Dammann O, Leviton A. Inflammation, brain damage and visual dysfunction in preterm infants.  Semin Fetal Neonatal Med. 2006;  11 363-368
    CrossrefPubMedGoogle Scholar

APPENDIX 1

List of participating institutions and site investigators (The IV Ibuprofen Clinical Trials Group):

  • University of Texas Southwestern Medical Center, Dallas, TX: Blaire Cox, M.D. (deceased), Charles Rosenfeld, M.D.

  • Univ Hosp Antwerp, Belgium: Bart Van Overmeire, M.D., Ph.D., Pat Van Reempts, M.D., Ph.D.

  • Sharp Mary Birch Hospital, University of California PPRU, San Diego, CA: Paul Wozniak, M.D.

  • University of Miami, Jackson Memorial Hospital, Miami, FL: Ilene Sosenko, M.D.

  • University of Alabama, Birmingham, AL: Waldemar Carlo, M.D., Robert Schelonka, M.D.

  • Children's Hospital of Michigan, Wayne State University, Detroit, MI: Virginia Delaney-Black, M.D., Ron Thomas, Ph.D., J. Parker, G. Steinhilber

  • Children's Hospital of New York City, New York, NY: Richard Polin, M.D.

  • University of Utah Medical Center, Salt Lake City, UT: Robert Ward, M.D.

  • Dornbecher Children's Hospital/OHSU, Portland, OR: Linda Wallen, M.D.

  • New York Medical College Westchester Medical Center, Westchester, NY: Lance Parton, M.D.

  • Winthrop University Hospital, Mineola, NY: Jonathan Davis, M.D., Linda Genen, M.D., Carolyn Levine, M.D., Donna Better, M.D., Carlos Montoya, M.D.

  • Ross Abbott IV Ibuprofen Trial Team, Columbus, OH: Kevin Mahan, Ph.D., Alan Ryan, Ph.D., Robert Shalwitz, M.D., Gregory Gomez, Anand Seth, Ph.D., Geraldine Baggs, Ph.D., Jeffery Oliver, M.S., Susan Toth, M.P.H., Linna Liu, M.S., Sue Zhang, M.S., Nel VanLommel, Mark Poulson, Kelly Samaie, Veronica Knox, Mary Ann Cockram, Jerry Young, M.P.H., Charles Paule, M.S., Kristen Deluca, R.D., L.D., M.S., and Bobbie Swearengin, R.N.

  • Data Safety Monitoring Committee: Ronald Clyman, M.D. (UCSF), Yvette Johnson, M.D., M.P.H. (Baylor) (Chair), Leonard Weissman, M.D. (Baylor); Stanley Lemeshow, Ph.D. (OSU)

The NICHD Pediatric Pharmacology Research Unit Network (NICHD PPRU), Children's Hospital of Michigan and Wayne State University, Detroit, MI, and the Intravenous Ibuprofen Clinical Trial Group.

0 Deceased.

Jacob V ArandaM.D. 

Professor and Director of Neonatology, Pediatric Pharmacology Research Unit Network, The Children's Hospital of Brooklyn, State University of New York Downstate Medical Center

450 Clarkson Avenue, Box 49, Brooklyn, New York City, NY 11023

Email: jaranda@downstate.edu

      >